Vnitřní lékařství 4/2021

HLAVNÍ TÉMA Biologická léčba dyslipidemií | 211 14. Schwartz GG, Steg PG, Szarek M et al. ODYSSEY OUTCOMES Committees and Investi- gators. Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097–2107. 15. Steg PG, Szarek M, Bhatt DL et al. Effect of Alirocumab on Mortality After Acute Coro- nary Syndromes. Circulation 2019; 140: 103–112. 16. Jukema JW, Szarek M, Zijlstra LE et al. ODYSSEY OUTCOMES Committees and Investi- gators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syn- drome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019; 74: 1167–1176. 17. Goodman SG, Aylward PE, Szarek M el al. ODYSSEY OUTCOMES Committees and In- vestigators. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Sur- gery. J Am Coll Cardiol 2019; 74: 1177–1186. 18. Schwartz GG, Steg PG, Szarek M et al. ODYSSEY OUTCOMES Committees and Investiga- tors. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 2020; 141: 1608–1617. 19. Bittner VA, Szarek M, Aylward PE et al. ODYSSEY OUTCOMES Committees and Investi- gators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coro- nary Syndrome. J Am Coll Cardiol 2020; 75: 133–144. 20. Ray KK, Colhoun HM, Szarek M et al. ODYSSEY OUTCOMES Committees and Investiga- tors. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coro- nary syndrome in patients with or without diabetes: a prespecified analysis of the ODY- SSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7: 618–628. 21. Ridker PM, Revkin J, Amarenco P et al. SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med 2017; 376: 1527–1539. 22. Ridker PM, Tardif JC, Amarenco P et al. SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med 2017; 376: 1517–1526. 23. Cui Y, Huo Y, Li X et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. Eur Heart J 2020; doi.org/10.1093/ehjci/ehaa946.3327. 24. Pisciotta L, Favari E, Magnolo L et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ Cardio­ vasc Genet 2012; 5: 42–50. 25. Ahmad Z, Banerjee P, Hamon S et al. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation 2019; 140: 470–486. 26. Raal FJ, Rosenson RS, Reeskamp LF et al. ELIPSE HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383: 711–720. 27. Rosenson RS, Burgess LJ, Ebenbichler CF et al. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med 2020; 383: 2307–2319. 28. Macchi C, Sirtori CR, Corsini A et al. A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacol Res 2019; 150: 104413. 29. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/new- -drugs-coming-up-in-the-field-of-lipid-control. 30. Ray KK, Landmesser U, Leiter LA et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017; 376: 1430–1440. 31. Wright RS, Collins MG, Stoekenbroek RM et al. Effects of Renal Impairment on the Phar- macokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc 2020; 95: 77–89. 32. Hovingh GK, Lepor NE, Kallend D et al. Inclisiran Durably Lowers Low-Density Lipo- protein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Ho- mozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation 2020; 141: 1829–1831. 33. Raal FJ, Kallend D, Ray KK et al. ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020; 382: 1520–1530. 34. Ray KK, Wright RS, Kallend D et al. ORION-10 and ORION-11 Investigators. Two Pha- se 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020; 382: 1507–1519. 35. GrahamMJ, Lee RG, Brandt TA et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med 2017; 377: 222–232. 36. Tirronen A, Hokkanen K, Vuorio T, Ylä-Herttuala S. Recent advances in novel therapies for lipid disorders. Hum Mol Genet 2019; 28: R49–R54. 37. Zwol WV, Rimbert A, Kuivenhoven JA. The Future of Lipid-lowering Therapy. J Clin Med 2019; 8: 1085. 38. Witztum JL, Gaudet D, Freedman SD et al. Volanesorsen and Triglyceride Levels in Fa- milial Chylomicronemia Syndrome. N Engl J Med 2019; 381: 531–542. 39. Gouni-Berthold I, Alexander V, Digenio A et al. Apolipoprotein C-III inhibition with vo- lanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-b- lind, placebo-controlled trial. Atheroscler Suppl 2017; 28: e1–e2. 40. Gelrud A, Digenio A, Alexander V et al. Treatment with volanesorsen (VLN) reduced triglycerides and pancreatitis in patients with FCS and sHTG vs placebo: results of the APPROACH and COMPASS. J Clin Lipidol 2018; 12: 537. 41. https://ir.ionispharma.com/news-releases/news-release-details/akcea-and-ionis-re- port-top-line-results-broaden-study-waylivrar. 42. Alexander VJ, Xia S, Hurh E et al. N-acetyl galactosamine-conjugated antisense drug to APOC3mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J 2019; 40: 2785–2796. 43. Tsimikas S, Viney NJ, Hughes SG et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386: 1472–1483. 44. Viney NJ, van Capelleveen JC, Geary RS et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388: 2239–2253. 45. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I et al. AKCEA-APO(a)-LRx Stu- dy Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med 2020; 382: 244–255. Získejte také nové aktuální informace a kredity v rámci celoživotního vzdělávání ➜ https://online.solen.cz Rádi vám pomáháme v on-line vzdělávání 23 on-line kurzů a kongresů 7200 účastníků 160 přednášek 1340 vydaných certi kátů